NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-08-31
Reading VTRS? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →Intact: The reason to own it still holds.
Viatris aims for about $14.7B revenue in 2026. Free cash flow should reach $2.15B. New products brought $71M revenue in Q1. The company is cutting costs to improve profits.
Revenue growth is slow and guidance was cut recently. The company is still loss making. Cost cuts may not be enough to fix problems.
The price is about 20% below our fair value near $21. Analysts expect about 2% revenue growth. We see risk from recent guidance cuts and cost issues.
Breaks if: Cost savings do not materialize or reverse in 2026
Breaks if: Free cash flow falls below $2.0B in FY26
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a turnaround story with a focus on cost savings and product launches. The current thesis state is intact, supported by recent financial performance, but management's execution remains critical.
The market seems to price in a low expectations gap, indicating that VTRS is viewed as relatively cheap compared to peers. However, there is a medium level of confidence in the valuation, suggesting that investors are cautious about future performance.
Fundamentals are likely to improve as management executes on cost-saving measures and advances product launches. Recent financial performance has been strong, but the company operates in a high-miss-rate industry, which adds some risk.
The thesis hinges on management's ability to maintain guidance and execute on strategic priorities. Additionally, the performance of sector bellwethers and overall economic conditions will significantly impact VTRS's trajectory.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The latest earnings beat supports this improved outlook. There are no new threats identified that could weaken the thesis.
as of 2026-08-31
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Viatris reaffirms its 2026 financial guidance, maintaining revenue and cash flow targets.
Breaks if: New product revenue fails to grow beyond $71M in Q1 run rate
Breaks if: Revenue falls below $13.9B in FY26
Viatris reaffirms its 2026 financial guidance, maintaining revenue and cash flow targets.
In the next 1 to 3 years, VTRS's performance will depend on effective management execution and external market conditions. Not investment advice.
